Healthcare & Life Sciences

86 Patients Study Breast Clip Visibility Twinkling Artifact

86 Patients Study Breast Clip Visibility Twinkling Artifact

Phase 3 Trial Comparing Perioperative, Adjuvant, Neoadjuvant Toripalimab for NSCLC

Phase 3 Trial Comparing Perioperative, Adjuvant, Neoadjuvant Toripalimab for NSCLC

Hybrid body awareness intervention improves menstrual outcomes

Hybrid body awareness intervention improves menstrual outcomes

Feasibility Study, Co-designed Pre-radiotherapy Exercise, Lung Cancer

Feasibility Study, Co-designed Pre-radiotherapy Exercise, Lung Cancer

Multilevel Hearing Protection Training for Farmworkers, Apr 28

Multilevel Hearing Protection Training for Farmworkers, Apr 28

Phase 1b Study of TRICK-NK With T-Dxd in Treatment-Refractory Breast Cancers

A Phase 1b clinical trial (NCT07553390) evaluating TRICK-NK (TGFBR-2 KO CD70 CAR NK cells) in combination with trastuzumab deruxtecan (T-Dxd) in participants with treatment-refractory breast cancers has been registered. The study comprises dose escalation (Part 1), dose expansion (Part 2), and an optional schedule optimization phase testing shorter intervals between NK cell infusion and T-Dxd dosing. The trial will assess maximum tolerable dose and safety of the combination regimen.

Photobiomodulation for Reticular Pseudodrusen, 12-Month Trial

Photobiomodulation for Reticular Pseudodrusen, 12-Month Trial

Plasma Therapy Observational Study, 500 Patients, China

Plasma Therapy Observational Study, 500 Patients, China

CMD Diet Pilot Trial for Recurrent Glioma Patients

This registry entry documents a new randomized, blinded interventional pilot study (NCT07553520) testing a cysteine/methionine deprivation (CMD) diet in up to 30 patients with recurrent glioma. Participants will be assigned to either a control diet or CMD diet for 2, 4, or 7 days before standard treatment, with researchers measuring glutathione metabolite levels, tumor cell behavior, and gut bacteria. Patients will be followed for progression-free survival and overall survival for up to 1 year.

Bio-flexible Spinal Fixation Apparatus for Preventing Fatigue Fracture

USPTO granted Patent US12611232B2 to inventor Kyung-Woo Park on April 28, 2026, for a bio-flexible spinal fixation apparatus designed to prevent fatigue fracture after spinal fixation surgery. The device features an eccentric coil rod design allowing natural flexion and extension motion post-surgery, with the rod including a straight part and a coil part wound at a predetermined angle. The patent application (18329250) was filed June 5, 2023, and the patent contains 11 claims under CPC classifications A61B 17/7028 and A61B 17/7005.

US12611233B2 Bone anchor housing limiter

The USPTO granted Patent No. US12611233B2 to Highridge Medical, LLC on April 28, 2026. The patent covers a bone anchor system comprising a fastener with a shaft, anchoring projection, and head; a rod housing connected to the fastener head; and a directional component with an outer diameter larger than the shaft diameter. The directional component includes a locking mechanism configured to engage the rod housing to limit housing movement during surgical fixation procedures. The patent contains 22 claims and was filed on January 23, 2024. Medical device manufacturers developing orthopedic surgical fixation products should evaluate this intellectual property for licensing or design-around considerations.

Spinal Rod Patent US12611231B2, Spinal Resources, 28th Apr

USPTO granted patent US12611231B2 to Spinal Resources, Inc. on April 28, 2026. The patent covers spinal rods comprising at least two segments with different constant diameters connected by a tapered transition region, plus at least one curve extending along the segments. The filing date was December 7, 2023, with application number 18532262.

Universal Fixator Clamp, Orthopedic Designs, Apr 28

USPTO granted patent US12611229B2 to Orthopedic Designs North America, Inc. on April 28, 2026, for a universal fixator clamp used in external fixation systems. The invention includes a torquing apparatus with multiple arms that engage complementary recesses in a proximal head to prevent patients from disengaging the clamp once tightened. The patent application (18612547) was filed on March 21, 2024, and the granted patent contains 6 claims.

Spinal Fixation Polyaxial Pedicle Screw Assigned to VB Spine US Opco LLC

The USPTO granted US Patent 12611234B2 on April 28, 2026, to assignee VB Spine US Opco LLC for a polyaxial pedicle screw system used in spinal fixation surgeries. The patent, invented by Larry E. McClintock, contains 15 claims covering the screw's housing, bone screw member, friction plug, anvil, and compression ring or cap configuration. This grant establishes exclusive IP rights for the disclosed spinal fixation device architecture.

Smith & Nephew Patent, Detachable Geared-Motor Strut Assembly for Spatial Frames

The USPTO granted Patent US12611228B2 to Smith & Nephew, Inc. on April 28, 2026, covering a detachable geared-motor assembly for motorizing a strut in a spatial frame. The patent claims priority to Application No. 18839091, filed February 14, 2023, and contains 23 claims under CPC classifications A61B 17/645, A61B 17/66, A61B 2017/00221, and A61B 2017/00398. Inventors include Paul Bell, Sied Janna, Darren J. Wilson, Andrew P. Noblett, Brian Roberts, Johnny R. Mason, and Scott Smyth. The geared-motor assembly is described as a standalone device including a microprocessor, printed-circuit board, and power supply for controlling the strut without external wires or a centralized controller. Competitors developing motorized spatial frame systems should review this patent for potential infringement exposure.

Vanderbilt University Patent, Medical Device Delivery System

Vanderbilt University has received US Patent 12611227B2 titled 'Medical device delivery apparatus and method.' The patent covers a delivery device configured to deliver a medical device into a patient, including a distal ring, transition tunnel, and proximal chute. The patent was granted on April 28, 2026 with 18 claims and a filing date of May 28, 2021. This patent represents intellectual property protection for medical device delivery technology developed by Kent K. Higdon.

Newmanbrain Brainwave Reading Apparatus Design USD1124354S1

The USPTO granted design patent USD1124354S1 to Newmanbrain, S.L. for a brainwave reading apparatus on April 28, 2026. The patent application was filed on October 22, 2024 under application number 29969433, with one claim covering the ornamental design of the device. The patent covers CPC classifications spanning brainwave monitoring, neurostimulation, and optical display components.

Electrode Patch, USD1124357S1, Y-BRAIN INC

Design patent USD1124357S1 for an electrode patch for biological signal measurement was granted to Y-BRAIN INC. by the USPTO. The patent application was filed on April 30, 2025, assigned application number 30001972, with one design patent claim. The CPC classifications span multiple medical device categories including A61B 5/0404, A61B 5/0416, A61B 5/0422, A61B 5/0424, A61B 5/04012, A61B 5/04082, A61B 5/04085, A61B 5/04087, A61B 5/6841, A61N 1/046, A61N 1/0472, and A61N 1/0476.

Medtronic Implantable Cardiac Monitor Design Patent USD1124345S1

The USPTO granted Medtronic, Inc. Design Patent USD1124345S1 for an implantable cardiac monitor on April 28, 2026. The patent application was filed on April 30, 2024 under Application No. 29940020, with three inventors: Matthew T. Vanderpool, Michael R. Klardie, and Kris A. Peterson. The patent contains one design claim covering the ornamental appearance of the medical device.

Electrode Patch Design Patent USD1124356S1 by Y-BRAIN INC

The USPTO granted Design Patent USD1124356S1 to Y-BRAIN INC on April 28, 2026, for an electrode patch for biological signal measurement. The patent was filed on April 30, 2025, under application number 30001969, with inventors Yoon Kyoung Hong, Tae Nam Kim, and Ki Won Lee. CPC classifications span A61B diagnostic/surgical categories and A61N electrotherapy categories.

Nitrile SUMO Inhibitors for Cancer Treatment

The USPTO granted Patent US12612414B2 to CIT Therapeutics, Inc. on April 28, 2026, covering nitrile-containing compounds that inhibit Small Ubiquitin-like Modifier (SUMO) proteins. The patent includes 18 claims and names six inventors: Miles Douglas Kubota, Andrew S. Tasker, Fang-Tsao Hong, Mary Walton, Victor J. Cee, and Peter Buchowiecki. The compounds are directed toward use in cancer treatment, with CPC classification C07D 495/04 in organic chemistry.

Vertex CFTR Modulator Patent Cystic Fibrosis Apr 28 2026

The USPTO granted Patent US12612416B2 to Vertex Pharmaceuticals Incorporated on April 28, 2026, covering modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) with the core structure. The patent includes 23 claims and covers pharmaceutical compositions containing at least one such modulator, methods of treating cystic fibrosis, combination therapies, and processes and intermediates for making the modulators. The application was filed on October 6, 2021, under Application No. 18248065.

Cystic Fibrosis Foundation Granted Patent on CFTR Potentiators

The USPTO granted Patent US12612409B2 to the Cystic Fibrosis Foundation on April 28, 2026, covering pyrrolopyrimidine compounds as potentiators of the Cystic Fibrosis Transmembrane conductance Regulator (CFTR). The patent names nine inventors and discloses pharmaceutical compositions and methods of treatment for cystic fibrosis, asthma, bronchiectasis, COPD, constipation, diabetes mellitus, dry eye disease, pancreatitis, rhinosinusitis, and Sjögren's Syndrome. The patent contains 20 claims and was filed under CPC classification C07D 487/04.

BeOne Medicines I GmbH TLR7 Agonist Patent US12612407B2

The USPTO granted BeOne Medicines I GmbH patent US12612407B2 covering imidazo[2,1-f][1,2,4]triazin-4-amine derivatives and their stereoisomers and salts as TLR7 agonists for cancer treatment. The patent contains 14 claims and was applied for on February 6, 2020. This grant provides BeOne Medicines with enforceable intellectual property rights that may affect freedom-to-operate for other developers of TLR7-targeted cancer immunotherapies.

Pyrazolone-Fused Pyrimidine Compound, Preparation Method and Applications Thereof

USPTO granted Patent US12612408B2 to Shanghai Pharmaceuticals Holding Co., Ltd. on April 28, 2026. The patent covers a pyrazolone-fused pyrimidine compound represented by formula (II) with improved inhibitory activity against WEE1 kinase, a protein target relevant to cancer therapy research. The filing date was June 28, 2020, under Application No. 17622579, with 20 claims allowed.

Institut Pasteur Granted Patent on Imidazopyrazine Luciferin Derivatives

The USPTO granted Institut Pasteur patent US12612411B1 for imidazopyrazine derivatives, their preparation processes, and uses as luciferins in bioluminescence applications for biology and medicine. The patent, with 6 claims, covers CPC classifications C07D 487/04, A61K 49/0013, G01N 21/763, and G01N 33/573. Institut Pasteur now holds exclusive rights to these compounds, which have applications in bioluminescent assay and imaging technology development.

Accro Bioscience Granted Patent, Heteroaryl Necrosis Inhibitors

USPTO granted patent US12612413B2 to Accro Bioscience (HK) Limited on April 28, 2026, covering heteroaryl compounds of Formula I as inhibitors of the programmed necrosis pathway, pharmaceutical compositions containing them, and methods of treatment using the same. The patent application (No. 17790728) was filed January 4, 2021, under CPC classification C07D 495/04, with 16 claims. Inventors are Xiaohu Zhang, Haikuo Ma, and Sudan He. This grant confers exclusive rights to the assignee for the patented subject matter, which relates to treating diseases and disorders arising from or related to programmed necrosis.

Multi-cyclic IRAK and FLT3 Inhibiting Compounds and Uses Thereof

Children's Hospital Medical Center has been granted US Patent No. US12612410B2 for multi-cyclic compounds that inhibit IRAK and FLT3. The patent, filed on December 23, 2021 and granted on April 28, 2026, contains 20 claims covering pharmaceutical compositions and methods of treating diseases including hematopoietic cancers, myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML). The invention also encompasses combination therapies with other cancer treatments.

Nutshell Therapeutics Granted Patent for Nitrogen Sulfonamide Cancer Compounds

USPTO granted patent US12612402B2 to Nutshell Therapeutics (Shanghai) Co., Ltd. on April 28, 2026, covering nitrogen-containing fused heterocyclic compounds of N-sulfonamide and their use in cancer treatment. The patented compounds promote binding of p53 Y220C mutant with DNA and exhibit inhibitory activity against cancer cell proliferation. Three inventors are listed: Guoqiang Zhou, Liting Yu, and Caiming Xi. The patent application was filed on January 17, 2025, with 15 claims.

Preparation method for (R)-1,2,3,4-tetrahydroisoquinoline-1-carboxylic acid, derivatives thereof and levo-praziquantel

USPTO granted Patent US12612398B2 to Tongli Biomedical Co., Ltd. on April 28, 2026, covering a preparation method for (R)-1,2,3,4-tetrahydroisoquinoline-1-carboxylic acid, derivatives thereof, and levo-praziquantel using immobilized lipase catalysis in a circulating fluidized bed reactor. The patent names five inventors: Jianping Wu, Lingjiao Tang, Xiao Zhan, Lirong Yang, and Mingxin Qian, with Application No. 17654974 filed March 15, 2022. The invention claims improved enzyme utilization, reduced enzyme/substrate ratio, mild reaction conditions, strong stereoselectivity, and high reaction efficiency. The patent contains 19 claims under CPC classification C07D 471/00.

Opilan Pharma S1P Receptor Modulator Crystalline Forms Patent - US12612401B2

The USPTO granted Opilan Pharma Limited Patent US12612401B2 for crystalline forms of an S1P receptor modulator, a heterocyclic compound classified under CPC C07D 471/04. The patent covers the chemical compound (R)-5-(2,5-dichloro-4-(5-(8-chloro-6-(trifluoromethyl)imidazo[1,2-a]pyridin-2-yl)-1,2,4-oxadiazol-3-yl)phenoxy)piperidin-2-one, salts, and solvates. The patent issued on April 28, 2026, with 20 claims and inventors John Nuss, Jason Harris, Shendong Yuan, and Scott Alan Wolckenhauer.

PSMA Binder Patent, Prostate Cancer Imaging Agent

USPTO granted Patent US12612343B2 to Shiya Pharmaceutical, Inc. on April 28, 2026 for a prostate specific membrane antigen (PSMA) binding compound and its radioactive isotope complex for use as a nuclear medicine tracer and imaging agent in prostate cancer diagnostics. The patent application (17642179) was filed April 13, 2021, and the granted patent contains 13 claims under CPC classifications A61P 35/04 and A61K 51/0455.

Edwards Lifesciences Automated Sewing Patent US12611209B2

The USPTO granted Patent US12611209B2 to Edwards Lifesciences Corporation on April 28, 2026, covering automated systems, devices, and methods for sewing prosthetic implant devices. The invention involves forming stitches on a target device, adjusting thread to clear the needle path, and applying targeted tension to tension the stitch during suturing. The patent names Wei Nee Koh, Ping-Yang Shih, Marius Tomas Petrulis, and Sam Nicolas Sarian as inventors, with 21 claims total.

Surgical Mesh with Ingrowth-Preventing Coating, 18 Claims

The USPTO granted Patent US12611293B2 to Sheridan Technologies LLC on April 28, 2026, covering a coated surgical mesh with a tissue ingrowth-preventing coating applied to one surface. The coating penetrates a controllable amount part way through the mesh. Inventors John W. Huelskamp and Andrew R. Leopold filed the application on February 13, 2024, under CPC classification A61F 2/0063. The patent contains 18 claims and is classified under the A61F prosthetics category.

Smith & Nephew Patent US12611230B2 Granted, 28th Apr

USPTO granted patent US12611230B2 to Smith & Nephew, Inc. on April 28, 2026, covering methods and systems for improved joint repair. The patent describes adjustable loop constructs with anchors, all-suture anchors, and locking passage mechanisms, with claims directed at reducing bone material removal and repair elongation over time. The application was filed March 4, 2022, as Application No. 18279799, containing 16 claims.

Emboline Catheter Delivery Device for Cardiac Valve

The USPTO granted Patent 12,611,294 B2 to Emboline, Inc. on April 28, 2026, covering a catheter system for delivering medical devices to cardiac valve regions. The system includes an elongate sheath with dual lumen configuration and an expandable embolic protection filter designed to shield side branch vessels in the aortic arch during procedures. The patent names Erik Krahbichler as inventor and contains 10 claims.

Transcranial Random Noise Stimulation Language Task Study

A Phase N/A clinical study registered on ClinicalTrials.gov (NCT07554105) evaluating transcranial random noise stimulation effects on language task performance in healthy adult participants. The study uses a randomized, double-blind, placebo-controlled crossover design with two sessions spaced approximately one week apart. Participants will undergo active or sham stimulation while performing language tasks, with brain activity recorded via EEG. The study does not provide direct benefit to participants, with risks limited to temporary sensations.

Tenosynovitis in Polyarticular and Oligoarticular Juvenile Idiopathic Arthritis

The National Institutes of Health registered an observational clinical study (NCT07553910) on April 28, 2026, investigating the frequency of tenosynovitis in pediatric patients diagnosed with polyarticular and oligoarticular juvenile idiopathic arthritis (JIA) at Assiut University Children Hospital. The study will enroll participants up to 16 years of age and use musculoskeletal ultrasound alongside standard clinical assessments to detect hidden tendon inflammation. Researchers aim to compare clinical examination findings with ultrasound imaging to improve early recognition and management of tendon inflammation in pediatric JIA patients.

Gastric Volume Comparison in Pediatric Patients Using Endotracheal Tube vs First- and Second-Generation Supraglottic Airway Devices

NCT07555080 is an observational clinical study registered on April 28, 2026, comparing gastric volumes in pediatric patients undergoing positive pressure ventilation across three airway management groups: endotracheal tubes, first-generation supraglottic airway devices (SADs), and second-generation SADs with gastric drainage channels. The study uses gastric ultrasound to measure post-ventilation gastric volume as its primary outcome, with a clinical threshold of 1.25 ml/kg associated with lower perioperative aspiration risk in pediatric cases. Second-generation SADs were designed specifically to mitigate regurgitation risk through integrated gastric drainage channels compared to first-generation devices.

Super Quinas Preschool Intervention, 80 Children, Maia Portugal

This is the clinical trial registration for NCT07553507, a quasi-experimental controlled study evaluating the 'Super Quinas in Preschool' programme on 24-hour movement behaviours and motor development in preschool children aged 3-6 years. The 12-week intervention consists of one structured 60-minute physical activity session per week, delivered by a qualified exercise professional in a public preschool in Maia, Portugal, with approximately 80 children across four classes. Baseline data collection occurred February-March 2026, with subsequent assessments planned through September 2026.

Comparative Study on the Medium- and Long-term Benefits of Prosthesis Selection in Total Knee Arthroplasty

This retrospective observational study registered on ClinicalTrials.gov (NCT07553871) aims to compare medium- and long-term clinical outcomes, safety, and economic benefits of different knee prosthesis brands used in primary unilateral total knee arthroplasty (TKA) at a single hospital. The study will include adult patients who underwent first-time unilateral TKA between January 1, 2022 and December 31, 2025, evaluating postoperative knee function, complications, length of hospital stay, quality of life, and medical costs. Results are expected to provide evidence to support prosthesis selection and optimize healthcare resource allocation.

Phase 1 Trial of Neural Stem Cell-Derived Exosomes for Moderate-to-Severe Early-Onset Alzheimer's Disease

NCT07554872 is a Phase 1 open-label clinical trial evaluating the safety, tolerability, and preliminary efficacy of neural stem cell-derived exosomes (NSC-EVs) administered intranasally to patients with moderate-to-severe early-onset Alzheimer's disease. The study will enroll 9 participants across 3 frequency-escalation cohorts receiving doses once every 3 days, once every other day, or once daily over a 28-day treatment period, with follow-up visits at 4, 8, and 24 weeks post-treatment. This trial represents an early-stage investigation into a novel cell-derived therapeutic approach for early-onset Alzheimer's.

Phase 1b Open-Label Study Evaluating Miricorilant Pharmacokinetics and Safety in Adult Patients With MASH

A Phase 1b open-label study evaluating the pharmacokinetics and safety of Miricorilant in adult patients with presumed metabolic dysfunction-associated steatohepatitis (MASH) has been registered on ClinicalTrials.gov under NCT07553663, with an April 28, 2026 registration date. The study targets patients with Nonalcoholic Steatohepatitis (NASH), MASH with compensated cirrhosis, MASLD, and NAFLD. This registry entry documents the study parameters and does not establish any compliance obligations.

60-Day Occipital Nerve Stimulation Observational Study for Headache

This prospective observational cohort study registered as NCT07553533 will evaluate clinical outcomes and health care resource utilization among adults undergoing temporary 60-day occipital nerve peripheral nerve stimulation (PNS) as part of routine care for refractory headache disorders. The study, posted on April 28, 2026, is classified as observational with occipital nerve PNS as the sole intervention. No firm or sponsor is named in the registry entry.

Single vs Double Layer Cesarean Closure Niche Risk

This clinical trial registration (NCT07554001) on ClinicalTrials.gov describes an observational study comparing the development of uterine niche after single layer versus double layer closure of cesarean incision. The trial identifies two intervention groups: single layer unlocked sutures and double layer unlocked sutures, with niche development as the primary outcome measure. The study was listed with an April 28, 2026 date.

Efficacy and Safety of Pegylated Interferon Alpha-2β in Patients With Hepatitis B-related Hepatocellular Carcinoma After Radical Resection

NCT07553767 is an Early Phase 1 clinical trial registered on ClinicalTrials.gov on April 28, 2026, evaluating the efficacy and safety of pegylated interferon alfa-2β (Peg-IFN-α-2β) combined with nucleos(t)ide analogues in patients aged 18 to 65 with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) after radical resection. The trial will assess HBsAg disappearance, seroconversion, HBV DNA levels, and recurrence-free survival over 1 to 5 years. Participants will receive either Peg-IFN-α-2β with first-line NAs (TDF, TAF, or TMF) or NAs alone.

HHS OIG Audit Finds $2.26M in Potentially Improper Medicare Telehealth Payments

The HHS OIG completed an audit of CMS Medicare Part B telehealth billing and identified $1,964,125 in potentially improper payments for 173,287 virtual check-in services and $298,200 for 10,237 e-visit services, totaling $2,262,325 in potentially improper payments during the audit period. The audit found that CMS and Medicare Administrative Contractors lacked system edits to detect payments at risk for noncompliance, and that CMS had not educated providers on proper billing requirements for virtual check-in and e-visit services. OIG made three recommendations to CMS, including developing system edits that could have saved up to $2.3 million during the audit period.

Design Patent USD1124351S1 - Medical Trolley Handle, GE Precision Healthcare, Apr 28 2026

The USPTO granted Design Patent USD1124351S1 covering the ornamental design of a medical trolley handle to GE Precision Healthcare LLC. The patent application was filed on January 19, 2024 under Application No. 29924707 and claims priority to a single claim. The invention relates to medical devices including dialysis equipment and patient monitoring systems as indicated by its CPC classifications.

Continuous Glucose Monitoring Transmitter Design Patent USD1124355S1

USPTO granted Design Patent USD1124355S1 on April 28, 2026, covering the ornamental design of a continuous glucose monitoring transmitter. The patent lists Bozhen Sun and Hao Hua as the sole inventors. The patent application was filed on December 25, 2024, under Application No. 35523724, and includes one design claim. CPC classifications span medical device monitoring systems, glucose measurement, and physiological signal processing.